医学
彭布罗利珠单抗
卡铂
危险系数
吉西他滨
肿瘤科
化疗
内科学
杜瓦卢马布
癌症
顺铂
置信区间
免疫疗法
作者
Thomas Powles,Begoña P. Valderrama,Shilpa Gupta,Jens Bedke,Eiji Kikuchi,Jean Hoffman‐Censits,Gopa Iyer,Christof Vulsteke,Se Hoon Park,Sang Joon Shin,Daniel Castellano,Giuseppe Fornarini,Jian‐Ri Li,Mahmut Gümüş,Nataliya Mar,Yohann Loriot,Aude Fléchon,Ignacio Durán,Alexandra Drakaki,Sujata Narayanan
标识
DOI：10.1056/nejmoa2312117
摘要
Treatment with enfortumab vedotin and pembrolizumab resulted in significantly better outcomes than chemotherapy in patients with untreated locally advanced or metastatic urothelial carcinoma, with a safety profile consistent with that in previous reports. (Funded by Astellas Pharma US and others; EV-302 ClinicalTrials.gov number, NCT04223856.).
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
无极微光
大力的灵雁
wanci
畔畔
Strawberry
dew
MP
hovumath
科研狗
热心市民小红花
你嵙这个期刊没买
乐空思
殷勤的紫槐
学术文献互助
小米
贪玩的秋柔
昏睡的蟠桃
邓佳鑫Alan
干净的琦
侯人雄
皖公网安备34019202002308
